---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113740"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:17:11.761734+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Alkermes hosts investor event to review orexin portfolio and development strategy

## Summary
- Presentation reviewed Alkermes' orexin portfolio on October 9, 2024.
- No specific financial or clinical data disclosed in the furnished exhibit.
- Investor event focused on development strategy for orexin programs.
- Filing under Item 7.01 (Regulation FD) with presentation as Exhibit 99.1.

## SEC filing metadata
- accession: 0000950170-24-113740
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017024113740/0000950170-24-113740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017024113740/alks-20241009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113740
- JSON: https://secwatch.observer/filing/0000950170-24-113740.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.